The high-stakes battle for dominance in the burgeoning obesity medication market has reached a new inflection point. In a significant shift for the pharmaceutical landscape, CVS Health’s pharmacy benefit manager (PBM) arm, CVS Caremark, has reached a new agreement that effectively reshapes the competitive terrain between the two titans of the industry: Eli Lilly and Novo Nordisk.
The agreement grants preferred status to Eli Lilly’s flagship injectable weight-loss drug, Zepbound, and brings its recently launched oral medication, Foundayo, into the fold. This move by CVS effectively nullifies a critical commercial advantage that Novo Nordisk had enjoyed for the better part of a year. The development marks a pivot in the strategy of PBMs, which are increasingly pressured to manage the skyrocketing costs of GLP-1 receptor agonists while balancing access for millions of patients.
Main Facts: The Changing Landscape of Weight-Loss Access
The core of the announcement is that CVS Caremark has moved to restore and expand coverage for Eli Lilly’s portfolio. For months, Novo Nordisk’s Wegovy held a distinct position of favor, creating a hurdle for patients and providers looking to access Zepbound.
By leveling the playing field, CVS has fundamentally changed how patients navigate the bureaucracy of insurance coverage. Analysts at Leerink Partners, led by David Risinger, were quick to highlight the significance of the move. In a note to investors, Risinger stated, "Today’s decision reverses the prior exclusivity advantage and meaningfully expands the addressable prescription pool for both Zepbound and Foundayo."
This expansion is not merely a bureaucratic change; it is a signal of the intense leverage drugmakers are exerting on PBMs to secure placement on formularies—the lists of covered medications that dictate what a patient pays at the pharmacy counter.
Chronology: A Year of Volatility in the GLP-1 Market
To understand the weight of this development, one must look back at the chaotic trajectory of the GLP-1 market over the past 18 months:
- Early 2024: Novo Nordisk secures a landmark deal with CVS Caremark, positioning Wegovy as a preferred option on key formularies. The market reacts swiftly; Eli Lilly shares face downward pressure as investors worry about potential long-term lockouts in the CVS network.
- Mid-2024: The "price war" escalates. Both companies begin exploring unconventional channels, including direct-to-consumer platforms and "employer connect" programs designed to bypass traditional insurance hurdles that often deny coverage for weight-loss medications.
- Late 2024: Novo Nordisk makes headlines by partnering with telehealth companies—including Hims & Hers—to provide access to GLP-1 treatments, a move aimed at capturing the self-pay market while maintaining brand integrity amidst the rise of compounded, "knockoff" alternatives.
- Early 2025: Political pressure mounts regarding the pricing of these drugs. Both Lilly and Novo Nordisk announce significant price cuts for Medicare patients, a strategic maneuver to appease regulators while capturing the massive elderly demographic.
- Current Date: The new CVS agreement is finalized, marking a ceasefire of sorts in the PBM-exclusionary tactics that characterized the previous year.
Supporting Data: Analyzing the Prescription Gap
The data surrounding these drugs reveals a stark reality: despite Eli Lilly’s market-leading efficacy profile, they have struggled to overcome the "first-mover" advantage that Novo Nordisk established with its earlier launch of Wegovy.
According to recent prescription data, while Zepbound has performed well, the adoption of Lilly’s oral entrant, Foundayo, has been slower than initial projections. Leerink Partners data suggests that the prescription trajectory for Foundayo in its first six weeks reached only 30% of the pace set by oral Wegovy.
This discrepancy is largely attributed to formulary access. In the world of specialty pharmaceuticals, a drug’s success is often decided before the patient even enters the doctor’s office. If a PBM places a drug on a "non-preferred" tier, the out-of-pocket costs can be prohibitive, effectively stifling adoption. By securing this new CVS deal, Lilly is attempting to close that 70% gap in adoption velocity. The company is banking on the fact that once the "friction" of insurance denial is removed, physicians will naturally gravitate toward the drug that provides the most robust weight-loss outcomes.
Official Responses and Corporate Strategy
The corporate rhetoric surrounding the deal highlights the delicate balance these companies must maintain.
Tom Scales, a senior vice president overseeing market access at Novo Nordisk, issued a measured response, emphasizing stability. "Wegovy products will retain preferred status on CVS Caremark formularies," Scales stated. "Nothing will change for the patients currently taking them. Both versions have strong formulary access across the U.S. market."
This statement is calculated to prevent a panic among current Novo users, ensuring they do not fear a sudden loss of coverage. It also reflects a reality of the current supply-demand imbalance: even with two major players, the demand for GLP-1s far outstrips the current manufacturing capacity of both companies.
Eli Lilly, conversely, has remained focused on the "total ecosystem" approach. By integrating Foundayo into the CVS agreement, they are signaling a move toward oral medications as the future of maintenance therapy for obesity, viewing the pill as a more convenient, scalable alternative to the weekly injection.
Implications: What This Means for Patients and the Future
The implications of this shift are profound, affecting three primary groups:
1. The Patients
For the millions of Americans struggling with obesity, this deal represents a significant victory in the form of reduced administrative friction. When PBMs open up access to multiple competing drugs, it encourages lower prices through competition. Patients will likely see more consistent coverage and potentially lower out-of-pocket costs as the two manufacturers compete for "preferred" status through deeper rebates and discounts.
2. The PBMs and Insurers
CVS Caremark is currently under intense scrutiny from Congress regarding how they manage drug prices and their relationships with pharmaceutical companies. By facilitating broader access to both Lilly and Novo products, CVS is attempting to position itself as a neutral arbiter that prioritizes patient access over exclusionary "rebate walls." This move may stave off some of the regulatory criticism they have faced regarding their role in the cost of chronic care medications.
3. The Market Dynamics
The "winner-take-all" mentality of the GLP-1 market is shifting toward a "co-existence" model. As both Lilly and Novo look toward the next generation of medications—including multi-agonist drugs that target GIP, GLP-1, and glucagon receptors—the competitive focus will move away from simple formulary access and toward clinical superiority.
However, the "Foundayo vs. Wegovy" pill war is only just beginning. As more oral GLP-1 candidates enter the pipeline, the ability to secure preferred placement in the PBM network will remain the most critical hurdle for pharmaceutical companies.
Conclusion: A New Phase of the Obesity Drug War
The inclusion of Foundayo in the CVS agreement is a testament to the fact that in the obesity drug market, science is only half the battle. The other half is the complex, often opaque world of pharmaceutical benefit management.
By restoring parity for Zepbound and providing a foothold for Foundayo, CVS has ensured that the next phase of this competition will be fought on the merits of the drugs themselves, rather than on the exclusionary fine print of insurance contracts. As both companies continue to slash prices for Medicare and expand into telehealth and employer-sponsored programs, the American patient stands to benefit—at least for now—from a marketplace that is finally being forced to prioritize access to drive volume.
Whether this trend of "open access" continues, however, remains to be seen. As the total expenditure for GLP-1 medications continues to climb toward the hundreds of billions of dollars, the pressure on PBMs to control costs will only grow, potentially leading to a new, even more aggressive round of negotiations in the years to come. For now, the scales have been rebalanced, and the race for the next million prescriptions is officially back on.
About the Author
